Zivo Bioscience Financials
This page shows Zivo Bioscience (ZIVOW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
New financing is still funding a development-stage expense base because customer revenue remains too small to carry operations.
FY2024 brought$5.6M of financing cash, yet year-end cash was only$1.5M . Paired with operating cash outflow of-$4.3M , that shows new capital was mostly absorbed by the operating engine rather than accumulated on the balance sheet.
Even after revenue reached
The balance sheet moved from deeply negative equity of
Financial Health Signals
Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Zivo Bioscience's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Zivo Bioscience carries a low D/E ratio of -4.19, meaning only $-4.19 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 92/100, indicating a strong balance sheet with room for future borrowing.
Zivo Bioscience's current ratio of 0.80 is below the typical benchmark, resulting in a score of 11/100. However, the company holds substantial cash reserves (76% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.
Zivo Bioscience passes 2 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Key Financial Metrics
Earnings & Revenue
Zivo Bioscience generated $157K in revenue in fiscal year 2024. This represents an increase of 468.6% from the prior year.
Zivo Bioscience earned $-4.23 per diluted share (EPS) in fiscal year 2024. This represents an increase of 8.0% from the prior year.
Cash & Balance Sheet
Zivo Bioscience held $1.5M in cash against $0 in long-term debt as of fiscal year 2024.
Zivo Bioscience had 4M shares outstanding in fiscal year 2024. This represents an increase of 52.0% from the prior year.
Margins & Returns
Zivo Bioscience's gross margin was 31.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 10.8 percentage points from the prior year.
Capital Allocation
Zivo Bioscience invested $3.1M in research and development in fiscal year 2024. This represents an increase of 127.7% from the prior year.
ZIVOW Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66K+22.9% | $53K | $0 | N/A | $32K | $0-100.0% | $36K | N/A |
| Cost of Revenue | $44K+25.0% | $35K | $0 | N/A | $22K | $0-100.0% | $23K | N/A |
| Gross Profit | $21K+18.8% | $18K | $0 | N/A | $9K | $0-100.0% | $13K | N/A |
| R&D Expenses | $203K-57.6% | $480K-82.7% | $2.8M | N/A | $326K-85.5% | $2.3M+620.1% | $313K | N/A |
| SG&A Expenses | $836K-28.6% | $1.2M-18.6% | $1.4M | N/A | $1.9M | N/A | $976K | N/A |
| Operating Income | -$1.0M+37.6% | -$1.6M+61.2% | -$4.2M | N/A | -$2.3M | N/A | -$1.3M | N/A |
| Interest Expense | $13K+76.1% | $7K+206.7% | $2K | N/A | $9K+26.5% | $7K+155.6% | $3K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Net Income | -$1.0M+37.0% | -$1.6M+61.1% | -$4.2M | N/A | -$2.3M | N/A | -$1.3M | N/A |
| EPS (Diluted) | $-0.27+37.2% | $-0.43+61.6% | $-1.12 | N/A | $-0.67+75.9% | $-2.78-491.5% | $-0.47 | N/A |
ZIVOW Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $559K-20.5% | $703K-47.2% | $1.3M-19.0% | $1.6M+231.6% | $496K-13.9% | $576K-29.5% | $816K+46.9% | $556K |
| Current Assets | $281K-31.3% | $410K-59.9% | $1.0M-37.5% | $1.6M+274.6% | $437K-11.8% | $495K-30.3% | $711K+67.1% | $425K |
| Cash & Equivalents | $57K+482.5% | $10K-98.1% | $517K-66.5% | $1.5M+867.6% | $159K+6364.0% | $2K-98.2% | $139K-49.5% | $274K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $0-100.0% | $34K | $0-100.0% | $2K-92.0% | $28K | $0-100.0% | $4K0.0% | $4K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.8M+18.6% | $3.2M+10.0% | $2.9M+36.6% | $2.2M-16.3% | $2.6M-10.2% | $2.9M-6.9% | $3.1M+11.7% | $2.8M |
| Current Liabilities | $3.6M+22.1% | $3.0M+13.3% | $2.6M+28.0% | $2.0M-20.8% | $2.6M-10.2% | $2.9M-6.9% | $3.1M+11.7% | $2.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$3.3M-29.4% | -$2.5M-57.1% | -$1.6M-214.1% | -$515K+75.3% | -$2.1M+9.3% | -$2.3M-1.2% | -$2.3M-2.9% | -$2.2M |
| Retained Earnings | -$143.9M-0.7% | -$142.8M-1.2% | -$141.2M-3.1% | -$137.0M-1.2% | -$135.4M-1.7% | -$133.1M-6.6% | -$124.9M-1.0% | -$123.6M |
ZIVOW Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$267K+44.0% | -$476K+66.7% | -$1.4M-57.9% | -$906K+16.5% | -$1.1M-74.0% | -$624K+63.3% | -$1.7M-137.4% | -$716K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $314K+1114.2% | -$31K-107.6% | $405K-82.3% | $2.3M+84.3% | $1.2M+154.8% | $487K-68.8% | $1.6M+416.1% | -$495K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ZIVOW Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.4%-1.1pp | 33.6% | N/A | N/A | 30.0% | N/A | 35.0% | N/A |
| Operating Margin | -1551.8%+1506.0pp | -3057.8% | N/A | N/A | -7174.7% | N/A | -3571.8% | N/A |
| Net Margin | -1574.2%+1497.4pp | -3071.6% | N/A | N/A | -7201.9% | N/A | -3579.2% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -184.7%+48.6pp | -233.2%+83.1pp | -316.3% | N/A | -457.8% | N/A | -156.6% | N/A |
| Current Ratio | 0.08-0.1 | 0.14-0.3 | 0.39-0.4 | 0.80+0.6 | 0.170.0 | 0.17-0.1 | 0.23+0.1 | 0.15 |
| Debt-to-Equity | -1.17+0.1 | -1.28+0.5 | -1.82+2.4 | -4.19-3.0 | -1.24+0.0 | -1.25+0.1 | -1.36-0.1 | -1.25 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$515K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.80), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Zivo Bioscience's annual revenue?
Zivo Bioscience (ZIVOW) reported $157K in total revenue for fiscal year 2024. This represents a 468.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Zivo Bioscience's revenue growing?
Zivo Bioscience (ZIVOW) revenue grew by 468.6% year-over-year, from $28K to $157K in fiscal year 2024.
What is Zivo Bioscience's gross margin?
Zivo Bioscience (ZIVOW) had a gross margin of 31.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Zivo Bioscience's operating cash flow?
Zivo Bioscience (ZIVOW) generated -$4.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Zivo Bioscience's total assets?
Zivo Bioscience (ZIVOW) had $1.6M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Zivo Bioscience spend on research and development?
Zivo Bioscience (ZIVOW) invested $3.1M in research and development during fiscal year 2024.
What is Zivo Bioscience's current ratio?
Zivo Bioscience (ZIVOW) had a current ratio of 0.80 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Zivo Bioscience's debt-to-equity ratio?
Zivo Bioscience (ZIVOW) had a debt-to-equity ratio of -4.19 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Zivo Bioscience's cash runway?
Based on fiscal year 2024 data, Zivo Bioscience (ZIVOW) had $1.5M in cash against an annual operating cash burn of $4.3M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Zivo Bioscience's debt-to-equity ratio negative or unusual?
Zivo Bioscience (ZIVOW) has negative shareholder equity of -$515K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Zivo Bioscience's Piotroski F-Score?
Zivo Bioscience (ZIVOW) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
How financially healthy is Zivo Bioscience?
Zivo Bioscience (ZIVOW) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.